MDPI Journal Highlights Potential of Oral-Derived Stem Cells in Regenerative Medicine

Researchers develop IGF-si-EV system, a novel nanovesicle treatment for osteoarthritis using oral-derived mesenchymal stem cells. The system shows promise in downregulating inflammation and promoting cartilage regeneration.

author-image
Bijay Laxmi
New Update
MDPI Journal Highlights Potential of Oral-Derived Stem Cells in Regenerative Medicine

MDPI Journal Highlights Potential of Oral-Derived Stem Cells in Regenerative Medicine

The International Journal of Molecular Sciences, an open-access journal published by MDPI, has released a special issue focused on the role of oral-derived mesenchymal stem cells in regenerative medicine. The issue highlights the potential of these stem cells in tissue regeneration and 3D-living constructs for future clinical applications.

Why this matters: The development of oral-derived mesenchymal stem cells has the potential to revolutionize the field ofregenerative medicine, offering new hope for the treatment of various diseases and injuries. As the global population ages, the demand for effective and innovative treatments will continue to grow, making breakthroughs like this crucial for improving healthcare outcomes.

Researchers have been actively exploring the therapeutic potential of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) in disease treatment, particularly in osteoarthritis (OA) therapy. A novel nanovesicle system, called IGF-si-EV, has been developed, which combines the properties of cartilage regeneration and long-term retention in the lesion site.

The IGF-si-EV system has been shown to downregulate inflammation-related cytokines and upregulate cartilage-regeneration-related factors, making it a promising OA treatment. The study, titled "Combinatory Nanovesicle with siRNA-Loaded Extracellular Vesicle and IGF-1 for Osteoarthritis Treatments," was published in the International Journal of Molecular Sciences (2024, 25, 5242).

The research team, led by Kim et al., used human umbilical cord MSC-derived EVs and functionalized them with insulin-like growth factor-1 (IGF-1) and siRNA to create the IGF-si-EV system. The study demonstrated the potential of the IGF-si-EV system as an effective OA treatment through its successful MMP13 inhibition, chondroprotective effect, and cartilage adhesion ability.

The development of the IGF-si-EV system could lead to a platform technology for various diseases, beyond OA treatment. The study highlights the potential of oral-derived mesenchymal stem cells in regenerative medicine, particularly in tissue regeneration and 3D-living constructs.

The International Journal of Molecular Sciences is an open-access journal that publishes original research articles, reviews, and communications on all aspects of molecular sciences. The journal is published by MDPI, a publisher of open-access journals that provides immediate access to all published articles under a Creative Commons license.

Key Takeaways

  • Oral-derived mesenchymal stem cells show potential in regenerative medicine.
  • IGF-si-EV system developed for osteoarthritis treatment with promising results.
  • System downregulates inflammation and upregulates cartilage regeneration.
  • Platform technology could be applied to various diseases beyond OA.
  • International Journal of Molecular Sciences publishes open-access research on molecular sciences.